首页> Clinical drug investigation> Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants.

Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants.

导出 OA

翻译打印收藏纠错

第一作者： Chiara,Bini

第一单位： Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", via Columbia 2, 00133, Rome, Italy. chiara.bini@uniroma2.it.

作者： Chiara,Bini ^[1] ; A,Marcellusi ^[2] ; D,Cazzato ^[3] ; B,Muzii ^[4] ; S,Soudani ^[5] ; E,Bozzola ^[6] ; F,Midulla ^[7] ; E,Baraldi ^[8] ; P,Bonanni ^[9] ; S,Boccalini ^[9] ; L,Orfeo ^[10]

作者单位： Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", via Columbia 2, 00133, Rome, Italy. chiara.bini@uniroma2.it. ^[1] Department of Pharmaceutical Sciences-DISFARM, University of Milan, via G. Colombo, 71, 20133, Milan, Italy. ^[2] Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", via Columbia 2, 00133, Rome, Italy. ^[3] Sanofi, Rome, Italy. ^[4] Sanofi, Lyon, France. ^[5] IRCCS Bambino Gesù Children Hospital, Rome, Italy. ^[6] Department of Maternal Science, Paediatric Emergency Service, Sapienza University of Rome, Rome, Italy. ^[7] Department of Woman's and Child's Health, University Hospital of Padova, Padua, Italy. ^[8] Department of Health Sciences, University of Florence, 50134, Florence, Italy. ^[9] Neonatal Intensive Care Unit, "Isola Tiberina Hospital-Gemelli Isola", 00186, Rome, Italy. ^[10]